Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.47 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.47 |
| ▸ | SOX18 | P35713 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996628 | 1.00 | CYP1A2 (0.58) | CYP1A2PDPK1FFAR1CTBP2HDAC1 | |
| SCHEMBL16595683 | 0.85 | CTBP2 (0.54) | CYP1A2PDPK1FFAR1CTBP2FFAR4 | |
| SCHEMBL7060418 | 0.82 | CYP1A2 (0.49) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL7060415 | 0.82 | CYP1A2 (0.49) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL16595881 | 0.82 | CYP1A2 (0.49) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL7061745 | 0.82 | CYP1A2 (0.52) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL7061744 | 0.82 | CYP1A2 (0.52) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL7061771 | 0.80 | CYP1A2 (0.47) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL7061768 | 0.80 | CYP1A2 (0.47) | CYP1A2PDPK1FFAR1HDAC1HDAC8 | |
| SCHEMBL16595075 | 0.80 | CYP1A2 (0.65) | CYP1A2PDPK1FFAR1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP1A2 1700/4885PDPK1 1683/4885FFAR1 1502/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP1A2 1700/4885PDPK1 1683/4885FFAR1 1502/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP1A2 1700/4885PDPK1 1683/4885FFAR1 1502/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP1A2 1700/4885PDPK1 1683/4885FFAR1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.